Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR

21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...

Read more →

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma

25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...

Read more →

Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes

8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba

24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...

Read more →

AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients

10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...

Read more →